0001883850-23-000094.txt : 20231213
0001883850-23-000094.hdr.sgml : 20231213
20231213160534
ACCESSION NUMBER: 0001883850-23-000094
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231211
FILED AS OF DATE: 20231213
DATE AS OF CHANGE: 20231213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHLEIFER LEONARD S
CENTRAL INDEX KEY: 0001218629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 231484003
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2023-12-11
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001218629
SCHLEIFER LEONARD S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
1
0
0
Bd. Co-Chair, President & CEO
0
Common Stock
2023-12-11
4
M
0
25155
A
387270
D
Common Stock
2023-12-11
4
F
0
12841
844.09
D
374429
D
Common Stock
250000
I
2023 GRAT
Common Stock
5916
I
By 401(k) Plan
Common Stock
64985
I
By Trust
2019 Performance Stock Units
2023-12-11
4
M
0
25155
D
Common Stock
25155
0
D
On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.
/s/**Leonard S. Schleifer
2023-12-13